BR112021024300A2 - Formas de sais cristalinas de um inibidor de quinase - Google Patents

Formas de sais cristalinas de um inibidor de quinase

Info

Publication number
BR112021024300A2
BR112021024300A2 BR112021024300A BR112021024300A BR112021024300A2 BR 112021024300 A2 BR112021024300 A2 BR 112021024300A2 BR 112021024300 A BR112021024300 A BR 112021024300A BR 112021024300 A BR112021024300 A BR 112021024300A BR 112021024300 A2 BR112021024300 A2 BR 112021024300A2
Authority
BR
Brazil
Prior art keywords
kinase inhibitor
salt forms
crystalline salt
crystalline
relates
Prior art date
Application number
BR112021024300A
Other languages
English (en)
Portuguese (pt)
Inventor
S Johnson Courtney
Frenel Demorin
Khalid Shah
Janelle Bevill Melanie
Peter Wong
Sagar Shakya
D Parent Stephan
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of BR112021024300A2 publication Critical patent/BR112021024300A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112021024300A 2019-06-03 2019-12-12 Formas de sais cristalinas de um inibidor de quinase BR112021024300A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962856404P 2019-06-03 2019-06-03
PCT/US2019/065980 WO2020247019A1 (en) 2019-06-03 2019-12-12 Crystalline salt forms of a kinase inhibitor

Publications (1)

Publication Number Publication Date
BR112021024300A2 true BR112021024300A2 (pt) 2022-01-11

Family

ID=69160360

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024300A BR112021024300A2 (pt) 2019-06-03 2019-12-12 Formas de sais cristalinas de um inibidor de quinase

Country Status (22)

Country Link
US (1) US20230052703A1 (cg-RX-API-DMAC7.html)
EP (1) EP3976587B1 (cg-RX-API-DMAC7.html)
JP (1) JP7579281B2 (cg-RX-API-DMAC7.html)
KR (1) KR102826380B1 (cg-RX-API-DMAC7.html)
CN (1) CN113939503B (cg-RX-API-DMAC7.html)
AU (1) AU2019449809B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021024300A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139148A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003205A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017343A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210616A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000236A (cg-RX-API-DMAC7.html)
ES (1) ES3008963T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20247655B (cg-RX-API-DMAC7.html)
IL (1) IL288484A (cg-RX-API-DMAC7.html)
MA (1) MA56001A (cg-RX-API-DMAC7.html)
MX (1) MX2021014773A (cg-RX-API-DMAC7.html)
PE (1) PE20220962A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021553020A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111978VA (cg-RX-API-DMAC7.html)
WO (1) WO2020247019A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202108034B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas
AU2022420610A1 (en) 2021-12-22 2024-06-27 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
CN116751161A (zh) * 2023-06-28 2023-09-15 中国人民解放军军事科学院军事医学研究院 喹啉类化合物及其制备方法、药物组合物及医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
SG187064A1 (en) * 2010-07-14 2013-02-28 Zhejiang Beta Pharma Inc NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
US20180009758A1 (en) * 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
MX2019012505A (es) * 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物

Also Published As

Publication number Publication date
GEAP202415849A (en) 2024-03-11
CO2021017343A2 (es) 2022-01-17
GEP20247655B (en) 2024-08-26
CN113939503B (zh) 2024-05-07
SG11202111978VA (en) 2021-11-29
WO2020247019A1 (en) 2020-12-10
KR20220016117A (ko) 2022-02-08
CA3139148A1 (en) 2020-12-10
MX2021014773A (es) 2022-01-18
MA56001A (fr) 2022-04-06
EP3976587B1 (en) 2024-12-04
CL2021003205A1 (es) 2022-09-30
EP3976587A1 (en) 2022-04-06
JP2022535072A (ja) 2022-08-04
CR20210616A (es) 2022-03-22
PH12021553020A1 (en) 2023-08-23
KR102826380B1 (ko) 2025-06-26
ES3008963T3 (en) 2025-03-25
DOP2021000236A (es) 2022-04-18
US20230052703A1 (en) 2023-02-16
PE20220962A1 (es) 2022-06-10
CN113939503A (zh) 2022-01-14
AU2019449809A1 (en) 2021-12-16
ZA202108034B (en) 2025-02-26
AU2019449809B2 (en) 2026-02-05
IL288484A (en) 2022-01-01
EP3976587C0 (en) 2024-12-04
JP7579281B2 (ja) 2024-11-07

Similar Documents

Publication Publication Date Title
EP4631505A3 (en) Crystalline forms and salt forms of a kinase inhibitor
BR112021023765A2 (pt) Composto de fórmula (1), um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, inibidor de aurora quinase, composição farmacêutica de combinação e aplicação do composto
CL2021003205A1 (es) Formas de sales cristalinas de un inhibidor de cinasas
BR112018002499A2 (pt) método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
EA201792214A1 (ru) Соединения замещенного хиназолина
BR112013021236A2 (pt) composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença
BR112015022785A2 (pt) composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
BR112023001792A2 (pt) Combinações para o tratamento de câncer
BR112017002403A2 (pt) formas de cristais de inibidores de glutaminase
MX2024010863A (es) Formas solidas, sales y procesos de preparacion de un inhibidor de cinasas dependientes de ciclina 2 (cdk2).
BR112021023927A2 (pt) Composto, e, composição farmacêutica
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112018073524A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição.
EA201990095A1 (ru) КОНДЕНСИРОВАННЫЕ ТИОФЕНОВЫЕ ПРОИЗВОДНЫЕ, ПРИЕМЛЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NAPI-IIb
BR112016020556A8 (pt) compostos, composição farmacêutica, método de modulação da atividade do receptor de grelina, método para o tratamento de uma doença e usos de um composto
BR112021024955A2 (pt) Inibidores de piridila ou pirimidila da quinase mtor
BR112017026272A2 (pt) ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto?
BR112022015925A2 (pt) Combinações de compostos beta-lactâmicos, probenecida e ácido valproico e usos dos mesmos
BR112017020053A2 (pt) novo composto heterocíclico, método para a preparação do mesmo e composição farmacêutica compreendendo o mesmo
BR112022024700A2 (pt) Inibidores de atr e usos dos mesmos
BR112021025079A2 (pt) Composto, uso de um composto, método para o tratamento ou profilaxia de doenças e condições afetadas pela modulação de tmem16a e composição farmacêutica
BR112019002151A2 (pt) usos de compostos de fórmula (i) e usos de uma composição
CY1124087T1 (el) Παραγωγα πυριδοκιναζολινης χρησιμα ως αναστολεις πρωτεϊνικων κινασων
EA202191653A1 (ru) Кристаллические формы и солевые формы ингибитора киназы
BR112021012817A2 (pt) Tratamento da síndrome de pitt-hopkins

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]